Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 trial of allogeneic iPS cell-derived corneal epithelial cell sheet (REM-01) for limbal stem cell deficiency
jRCT2053260029Phase 2Recruiting
- Sponsor
- Raymei
- Start
- May 2026
- Modality
- iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of REM-01 in limbal stem cell deficiency (LSCD), sponsored by Raymei. Primary endpoint: Success rate of corneal epithelial reconstruction at 52 weeks. Started May 2026; status: recruiting.
02
Drugs
REM-01
03
Conditions
limbal stem cell deficiency (LSCD)
Beyond the preview
Go deeper on jRCT2053260029.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2053260029.